Epic Patent-Cliff Exposure & CMS Drug Spending Portfolio

Epic (US): 12 reconciled FDA prescription therapies, $154.4M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies12
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$154.4M
2024 Medicare Part D Spend$81.9M
2024 Medicaid Spend$72.5M
California HCAI SB 17 Filings1 WAC filings (max 172.3% 2-yr change)